ARV-766 manufacturers
- Luxdegalutamide
-
- $318.00 / 1mg
-
2025-11-10
- CAS:2750830-09-0
- Min. Order:
- Purity: 99.95%
- Supply Ability: 10g
- Luxdegalutamide (ARV-766)
-
- $0.00 / 10mg
-
2025-03-16
- CAS:2750830-09-0
- Min. Order: 5mg
- Purity: 98%+ HPLC HNMR
- Supply Ability: 20g
|
| | ARV-766 Basic information |
| Product Name: | ARV-766 | | Synonyms: | 4-[4-[[1-[4-[[[trans-3-(4-Cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]amino]carbonyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-N-[(3S)-2,6-dioxo-3-piperidinyl]-2-fluorobenzamide;ARV776;Luxdegalutamide ARV-766;Luxdegalutamide | | CAS: | 2750830-09-0 | | MF: | C45H54FN7O6 | | MW: | 807.95 | | EINECS: | | | Product Categories: | | | Mol File: | 2750830-09-0.mol |  |
| | ARV-766 Chemical Properties |
| Boiling point | 993.4±65.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | solubility | DMSO: Soluble: =10 mg/ml | | form | Solid | | pka | 10.58±0.40(Predicted) | | color | White to off-white |
| | ARV-766 Usage And Synthesis |
| Uses | Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer[1][2]. | | in vivo | Luxdegalutamide exhibits anti-tumor activity in mouse LNCaP and VCaP xenograft models[2]. | | References | [1] Snyder L, et al. In vitro evaluation of PROTAC? degrader ARV-766 for cytochrome P450-and transporter-mediated drug-drug interaction[J]. Drug Metabolism and Pharmacokinetics, 2024, 55: 100881.
[2] Snyder L, et al. Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC? for the treatment of men with metastatic castration resistant prostate cancer[J]. Cancer Research, 2023, 83(7_Supplement): ND03-ND03. |
| | ARV-766 Preparation Products And Raw materials |
|